We are live on
!
Find out more
ADMA Biologics
ADMA
ADMA
19 hedge funds and large institutions have $45M invested in ADMA Biologics in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 0 closing their positions.
New
Increased
Maintained
Reduced
Closed
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
6% more funds holding
Funds holding: 18 → 19 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.12% less ownership
Funds ownership: 72.71% → 71.59% (-1.1%)
6% less capital invested
Capital invested by funds: $48M → $45M (-$2.95M)
Holders
19
Holders Change
+1
Holders Change %
+5.56%
% of All Funds
0.47%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
3
Increased
5
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
BlackRock
New York
|
+$94.1K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$52.1K |
| 3 |
SIM
Spark Investment Management
New York
|
+$26.7K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.9K |
| 5 |
PCM
Prelude Capital Management
New York
|
+$13.3K |
Top Sellers
| 1 |
BC
Broadfin Capital
New York
|
-$417K |
| 2 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$296K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$115K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$94 |
